<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358538</url>
  </required_header>
  <id_info>
    <org_study_id>1042-900</org_study_id>
    <nct_id>NCT02358538</nct_id>
  </id_info>
  <brief_title>A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies</brief_title>
  <official_title>A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of open-label ganaxolone as adjunctive therapy for uncontrolled
      seizures in female children with PCDH19 mutation and other rare genetic epilepsies in an
      open-label proof-of-concept study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this proof-of-concept study is to evaluate ganaxolone as adjunctive therapy
      for uncontrolled seizures in female children with PCDH19 mutations and other rare genetic
      epilepsies. After establishing baseline seizure frequency, qualifying subjects will enter
      the study and be treated with open-label ganaxolone for up to six months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in seizure frequency per 28 days relative to baseline calculated using daily seizure diary.</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression of Change score as assessed by questionnaire.</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change score as assessed by questionnaire.</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety and tolerability of open-label ganaxolone as adjunctive therapy for uncontrolled seizures in children with rare genetic epilepsies, based on adverse event log and other clinical safety assessments.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rates</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure free days</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum of 1800 mg/day or 63 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>oral suspension or capsules</description>
    <arm_group_label>Ganaxolone</arm_group_label>
    <other_name>CCD 1042</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Have parent or legal guardian available and willing to give written informed consent.

          2. Male and female outpatients between 2 and 18 years of age years of age at time of
             consent.

          3. Have any of the following epilepsy syndromes: PCDH19; CDKL5; Dravet Syndrome; Lennox
             Gastaut Syndrome (LGS); Continuous Spikes and Waves during Sleep (CSWS)

          4. Have uncontrolled cluster seizures and/or non-clustered seizures.

          5. Subjects should be on a stable regimen of anti-epileptic medication, and generally in
             good health.

          6. Parent or guardian is able and willing to maintain an accurate and complete daily
             written seizure calendar.

          7. Able and willing to take study medication with food, two or three times daily.

        Key Exclusion Criteria

          1. Have had previous exposure to ganaxolone.

          2. Known sensitivity or allergy to any component in the study drug, progesterone, or
             other related steroid compounds.

          3. Exposure to any investigational drug or device &lt; 90 days prior to screening, or plans
             to participate in another drug or device trial at any time during the study.

          4. Concurrent use of vigabatrin, tiagabine, or ezogabine is not permitted.

          5. Have any medical condition that, in the investigator's judgment, is considered to be
             clinically significant and could potentially affect subject safety or study outcome,
             including but not limited to: clinically significant cardiac, renal, pulmonary,
             gastrointestinal, hematologic or hepatic conditions; or a condition that affects the
             absorption, distribution, metabolism or excretion of drugs.

          6. Have active suicidal plan/intent, or have had active suicidal thoughts in the past 6
             months or a suicide attempt in the past 3 years.

          7. Have Alanine transferase (ALT; SGPT) or Aspartate transferase (AST; SGOT) levels &gt; 3
             times upper limits of normal (ULN), or total bilirubin &gt;1.5 time ULN at the screening
             and baseline visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaakko Lappalainen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Tsai, PhD</last_name>
    <phone>203-315-5820</phone>
    <email>jtsai@marinuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sutter Institute for Medical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Vulk</last_name>
      <phone>916-543-5746</phone>
      <email>VulkJ@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Chez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaleas Johnson</last_name>
      <phone>415-502-1921</phone>
      <email>Kaleas.Johnson@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Integrative Rare Disease Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gamze K Berkemen, PhD</last_name>
      <phone>404-498-3807</phone>
      <email>coordinator@cirdr.com</email>
    </contact>
    <investigator>
      <last_name>Thinh Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Tarquinio, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JWM Neurology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Mann</last_name>
      <phone>317-537-6088</phone>
      <phone_ext>1229</phone_ext>
      <email>kmann@jwmneuro.com</email>
    </contact>
    <investigator>
      <last_name>Keith Ridel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northeast Regional Epilepsy Group</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munazza Malik, MD</last_name>
      <phone>201-343-6676</phone>
      <email>mmalik@epilepsygroup.com</email>
    </contact>
    <investigator>
      <last_name>Eric Segal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology and Neurosurgery at St. Barnabas</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine DeCarlo, RN</last_name>
      <phone>973-322-7425</phone>
      <email>Elaine.DeCarlo@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Orrin Devinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Children's Hospital, IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Copponi, Dr. ssa</last_name>
      <email>giorgia.copponi@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Nicola Specchi, Dr. ssa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>January 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCDH19</keyword>
  <keyword>ganaxolone</keyword>
  <keyword>neurosteroid</keyword>
  <keyword>CDKL5</keyword>
  <keyword>LGS</keyword>
  <keyword>CSWS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
